Cargando…

The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports

Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Elena, Gurizzan, Cristina, Ottini, Arianna, Caspani, Francesca, Bergamini, Cristiana, Locati, Laura D., Marchiselli, Chiara, Alberti, Andrea, Lorini, Luigi, Licitra, Lisa F., Bossi, Paolo, Resteghini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013465/
https://www.ncbi.nlm.nih.gov/pubmed/36925925
http://dx.doi.org/10.3389/fonc.2023.1111146
_version_ 1784906802818711552
author Colombo, Elena
Gurizzan, Cristina
Ottini, Arianna
Caspani, Francesca
Bergamini, Cristiana
Locati, Laura D.
Marchiselli, Chiara
Alberti, Andrea
Lorini, Luigi
Licitra, Lisa F.
Bossi, Paolo
Resteghini, Carlo
author_facet Colombo, Elena
Gurizzan, Cristina
Ottini, Arianna
Caspani, Francesca
Bergamini, Cristiana
Locati, Laura D.
Marchiselli, Chiara
Alberti, Andrea
Lorini, Luigi
Licitra, Lisa F.
Bossi, Paolo
Resteghini, Carlo
author_sort Colombo, Elena
collection PubMed
description Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be treated with locoregional therapies. A minority of cases require systemic therapy. Currently, Sonic Hedgehog inhibitors (i.e., vismodegib and sonidegib) have been approved for advanced BCC, while the PD-1 checkpoint inhibitor cemiplimab has been approved as a first-line treatment for cSCC and as a second-line treatment for BCC. Nevertheless, there is a clinical need for an effective and safe systemic therapies for advanced synchronous (syn) BCC/cSCC not amenable to local treatments. International guidelines do not provide specific recommendations for patients affected by this condition, and no case reports on the full-dose association of these medications have been previously reported. Here, we present the cases of two elderly patients affected by synBCC/cSCC of the head and neck, who received combined therapy with cemiplimab and sonidegib at full dose and standard schedule, achieving remarkable clinical benefit and long-term responses, without major adverse events. The instance of a feasible treatment for patients with advanced synBCC/cSCC will become increasingly frequent with the advancement of life expectancy in the global population, and the synergistic activity of targeted therapies and immunotherapy—administered either in association or sequentially—deserves to be further explored.
format Online
Article
Text
id pubmed-10013465
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100134652023-03-15 The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports Colombo, Elena Gurizzan, Cristina Ottini, Arianna Caspani, Francesca Bergamini, Cristiana Locati, Laura D. Marchiselli, Chiara Alberti, Andrea Lorini, Luigi Licitra, Lisa F. Bossi, Paolo Resteghini, Carlo Front Oncol Oncology Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be treated with locoregional therapies. A minority of cases require systemic therapy. Currently, Sonic Hedgehog inhibitors (i.e., vismodegib and sonidegib) have been approved for advanced BCC, while the PD-1 checkpoint inhibitor cemiplimab has been approved as a first-line treatment for cSCC and as a second-line treatment for BCC. Nevertheless, there is a clinical need for an effective and safe systemic therapies for advanced synchronous (syn) BCC/cSCC not amenable to local treatments. International guidelines do not provide specific recommendations for patients affected by this condition, and no case reports on the full-dose association of these medications have been previously reported. Here, we present the cases of two elderly patients affected by synBCC/cSCC of the head and neck, who received combined therapy with cemiplimab and sonidegib at full dose and standard schedule, achieving remarkable clinical benefit and long-term responses, without major adverse events. The instance of a feasible treatment for patients with advanced synBCC/cSCC will become increasingly frequent with the advancement of life expectancy in the global population, and the synergistic activity of targeted therapies and immunotherapy—administered either in association or sequentially—deserves to be further explored. Frontiers Media S.A. 2023-02-28 /pmc/articles/PMC10013465/ /pubmed/36925925 http://dx.doi.org/10.3389/fonc.2023.1111146 Text en Copyright © 2023 Colombo, Gurizzan, Ottini, Caspani, Bergamini, Locati, Marchiselli, Alberti, Lorini, Licitra, Bossi and Resteghini https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Colombo, Elena
Gurizzan, Cristina
Ottini, Arianna
Caspani, Francesca
Bergamini, Cristiana
Locati, Laura D.
Marchiselli, Chiara
Alberti, Andrea
Lorini, Luigi
Licitra, Lisa F.
Bossi, Paolo
Resteghini, Carlo
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
title The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
title_full The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
title_fullStr The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
title_full_unstemmed The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
title_short The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
title_sort association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: two case reports
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013465/
https://www.ncbi.nlm.nih.gov/pubmed/36925925
http://dx.doi.org/10.3389/fonc.2023.1111146
work_keys_str_mv AT colomboelena theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT gurizzancristina theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT ottiniarianna theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT caspanifrancesca theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT bergaminicristiana theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT locatilaurad theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT marchisellichiara theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT albertiandrea theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT loriniluigi theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT licitralisaf theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT bossipaolo theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT resteghinicarlo theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT colomboelena associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT gurizzancristina associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT ottiniarianna associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT caspanifrancesca associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT bergaminicristiana associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT locatilaurad associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT marchisellichiara associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT albertiandrea associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT loriniluigi associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT licitralisaf associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT bossipaolo associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports
AT resteghinicarlo associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports